Results 321 to 330 of about 26,640,125 (414)

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana   +17 more
wiley   +1 more source

Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 984-993, April 2025.
Tumor‐informed whole‐genome sequencing (MRD‐EDGESNV) was applied to detect circulating tumor DNA (ctDNA) in patients with colorectal adenomas. Using a 95% specificity threshold, established from stage III colorectal cancer patients, ctDNA was detected in 50% of symptomatic and 25% of asymptomatic adenoma cases with median tumor fractions of 5.9 × 10−5 ...
Amanda Frydendahl   +13 more
wiley   +1 more source

Unraveling the molecular drivers of antibacterial prenylated (iso)flavonoids and chalcones against Streptococcus mutans. [PDF]

open access: yesSci Rep
van Dinteren S   +5 more
europepmc   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

open access: yesMolecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Cervical cancer screening: a comparative study of TruScreen vs. Pap Smear. [PDF]

open access: yesBMC Womens Health
Alhudhud M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy